Compare Dolby Laboratories, Inc. (DLB) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs 22nd Century Group Inc — how do they compare? Dolby Laboratories, Inc. trades at $58.71 (market cap $5.47B), while 22nd Century Group Inc trades at $0.84 (market cap $621.67K). The key difference: Dolby Laboratories, Inc. is far larger — about 8798.9× 22nd Century Group Inc's market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and 22nd Century Group Inc for 32 Days on average.
| DLB | XXII | |
|---|---|---|
Market Cap | $5.47B | $621.67K |
Volume | 1,058,284 | 45,625 |
Sector | Technology | Consumer Staples |
52-Week High | $70.09 | $483.00 |
52-Week Low | $48.51 | $0.80 |
Typical Hold Time | 98 Days | 32 Days |
Enterprise Value | $4.85B | -$3.69M |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLB trades at $58.90, up 0.94% with bearish technical signals but strong fundamentals including 87.61% gross margins and consistent earnings beats. Recent expansion with Meta and leadership transition to Marc Whitten highlight growth initiatives. Cash flow improved significantly to $215.61M in 2025 from negative trends.
Analyst consensus targets $90.33 (53% upside) with 47% buy ratings, though technical indicators signal caution. Key risks include licensing volatility and execution during leadership change. Revenue stability and premium valuation at 24.87 P/E support long-term case if growth accelerates.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
